BRIEF-Emergent Gets U.S. Contract Update for ACAM2000® Smallpox & Mpox Vaccine

Reuters

Sep 09

Sept 9 (Reuters) - Emergent BioSolutions Inc EBS.N:

EMERGENT BIOSOLUTIONS RECEIVES NEW CONTRACT MODIFICATION FOR ACAM2000®, (SMALLPOX AND MPOX (VACCINIA) VACCINE, LIVE) FROM THE U.S. GOVERNMENT, FURTHER DEMONSTRATING IMPORTANCE OF PUBLIC HEALTH PREPAREDNESS
EMERGENT BIOSOLUTIONS INC - ANNOUNCES $56 MILLION CONTRACT FOR ACAM2000 VACCINE
EMERGENT BIOSOLUTIONS INC - CONTRACT MODIFICATION UNDER EXISTING 10-YEAR ASPR CONTRACT

Source text: ID:nGNX7KGCzg

Further company coverage: EBS.N

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2566691225"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2566691225\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2566691225?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-09 19:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566691225","market":"us","top_or_hot":-1,"title":"BRIEF-Emergent Gets U.S. Contract Update for ACAM2000® Smallpox & Mpox Vaccine","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Emergent Gets U.S. Contract Update for ACAM2000® Smallpox &amp; Mpox Vaccine</title></head><body><p><span>Sept 9 (Reuters)</span><span> - </span>Emergent BioSolutions Inc <span>EBS.N</span>:</p><ul><li><p>EMERGENT BIOSOLUTIONS RECEIVES NEW CONTRACT MODIFICATION FOR ACAM2000®, (SMALLPOX AND MPOX (VACCINIA) VACCINE, LIVE) FROM THE U.S. GOVERNMENT, FURTHER DEMONSTRATING IMPORTANCE OF PUBLIC HEALTH PREPAREDNESS</p></li><li><p>EMERGENT BIOSOLUTIONS INC - ANNOUNCES $56 MILLION CONTRACT FOR ACAM2000 VACCINE</p></li><li><p>EMERGENT BIOSOLUTIONS INC - CONTRACT MODIFICATION UNDER EXISTING 10-YEAR ASPR CONTRACT</p></li></ul><p>Source text: <span>ID:nGNX7KGCzg</span></p><p>Further company coverage: <span>EBS.N</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Emergent Gets U.S. Contract Update for ACAM2000® Smallpox & Mpox Vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Emergent Gets U.S. Contract Update for ACAM2000® Smallpox & Mpox Vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-09 19:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Emergent Gets U.S. Contract Update for ACAM2000® Smallpox &amp; Mpox Vaccine</title></head><body><p><span>Sept 9 (Reuters)</span><span> - </span>Emergent BioSolutions Inc <span>EBS.N</span>:</p><ul><li><p>EMERGENT BIOSOLUTIONS RECEIVES NEW CONTRACT MODIFICATION FOR ACAM2000®, (SMALLPOX AND MPOX (VACCINIA) VACCINE, LIVE) FROM THE U.S. GOVERNMENT, FURTHER DEMONSTRATING IMPORTANCE OF PUBLIC HEALTH PREPAREDNESS</p></li><li><p>EMERGENT BIOSOLUTIONS INC - ANNOUNCES $56 MILLION CONTRACT FOR ACAM2000 VACCINE</p></li><li><p>EMERGENT BIOSOLUTIONS INC - CONTRACT MODIFICATION UNDER EXISTING 10-YEAR ASPR CONTRACT</p></li></ul><p>Source text: <span>ID:nGNX7KGCzg</span></p><p>Further company coverage: <span>EBS.N</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EBS","symbol_name":"Emergent Biosolutions","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250909:nTUA4DTLN3:1","article_id":"2566691225","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566691225","pubTimestamp":1757417637,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Emergent Gets U.S. Contract Update for ACAM2000 Smallpox & Mpox VaccineSept 9 (Reuters) - Emergent BioSolutions Inc EBS.N:EMERGENT BIOSOLUTIONS RECEIVES NEW CONTRACT MODIFICATION FOR ACAM2000, (","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EBS":"Emergent Biosolutions","BK4583":"猴痘概念","BK4139":"生物科技"},"translate_title":"BRIEF-Emergent获得美国ACAM2000合同更新®天花和Mpox疫苗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EBS":0.9},"content_text":"BRIEF-Emergent Gets U.S. Contract Update for ACAM2000® Smallpox & Mpox VaccineSept 9 (Reuters) - Emergent BioSolutions Inc EBS.N:EMERGENT BIOSOLUTIONS RECEIVES NEW CONTRACT MODIFICATION FOR ACAM2000®, (SMALLPOX AND MPOX (VACCINIA) VACCINE, LIVE) FROM THE U.S. GOVERNMENT, FURTHER DEMONSTRATING IMPORTANCE OF PUBLIC HEALTH PREPAREDNESSEMERGENT BIOSOLUTIONS INC - ANNOUNCES $56 MILLION CONTRACT FOR ACAM2000 VACCINEEMERGENT BIOSOLUTIONS INC - CONTRACT MODIFICATION UNDER EXISTING 10-YEAR ASPR CONTRACTSource text: ID:nGNX7KGCzgFurther company coverage: EBS.N ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}